About Omeros

To develop elegant solutions to complex problems, collaborative innovation is a necessity that we foster and celebrate. It’s not just part of the Omeros culture, it’s part of our fabric.

Who Is Omeros?

True innovation requires the right people, and that’s what we have at Omeros – smart, hard-working and creative individuals who collaborate and drive to achieve what has not yet been done. We see strength in diversity – diversity in thought, expertise and experience.

We have taken a similar approach in structuring our company. While many biotechs pursue a single therapeutic area or scientific platform, we are strategically building a deep and diverse pipeline of first-in-class small-molecule and antibody therapeutics. The strength of our scientific discoveries and exclusive intellectual property positions enable our pipeline programs to target highly promising receptors and enzymes that others have not been able to develop.

Although cutting across a wide and diverse range of disorders and therapeutic indications – some orphan, others large-market and many for which there are no approved treatments – all of our drugs on the market and in development target critical unmet needs to improve the lives of patients in meaningful ways.

Omeros at a Glance

Founded in 1994

Based in Seattle, WA on Elliott Bay in Lower Queen Anne

Number of employees: 250, as of April 1, 2019

Fully vertically integrated with one commercial product and multiple late- and early-stage assets

Publicly traded on NASDAQ (OMER)

Company Milestones

Present

OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1%/0.3% has been used in more than 600,000 ophthalmic procedures...and growing

We use cookies to ensure our website works properly and to collect statistics about users in order for us to improve the website. If you continue to browse this site, you will accept our use of cookies. For more information, please read our
Privacy Policy.

Agree

You are now leaving Omeros.com

Omeros makes no representation as to the accuracy of the information on sites we do not own or control and does not recommend or endorse content on any third-party websites. Your use of a third-party website is at your own risk and subject to the terms and conditions of that site.